{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:30:00Z","timestamp":1793691000154,"version":"4.5.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,31]]},"DOI":"10.7759\/cureus.106195","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:38:34Z","timestamp":1774967914000},"source":"Crossref","is-referenced-by-count":0,"title":["Global Research Trends in Gastric Cancer Epigenetics From 2005 to 2025"],"prefix":"10.7759","author":[{"given":"Didi","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01635-6","article-title":"The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","year":"2025","unstructured":"The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050. a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025, 406:1565-86. 10.1016\/S0140-6736(25)01635-6","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-020-09925-3","article-title":"Gastric cancer: a comprehensive review of current and future treatment strategies","volume":"39","author":"Sexton RE","year":"2020","unstructured":"Sexton RE, Al Hallak MN, Diab M, Azmi AS. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev. 2020, 39:1179-203. 10.1007\/s10555-020-09925-3","journal-title":"Cancer Metastasis Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-01771-5","article-title":"Environmental factors inducing gastric cancer: insights into risk and prevention strategies","volume":"16","author":"He P","year":"2025","unstructured":"He P, Li X, Zou D, Tang F, Chen H, Li Y. Environmental factors inducing gastric cancer: insights into risk and prevention strategies. Discov Oncol. 2025, 16:25. 10.1007\/s12672-025-01771-5","journal-title":"Discov Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyr184","article-title":"The epigenotype. 1942","volume":"41","author":"Waddington CH","year":"2012","unstructured":"Waddington CH. The epigenotype. 1942. Int J Epidemiol. 2012, 41:10-3. 10.1093\/ije\/dyr184","journal-title":"Int J Epidemiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/genes14040873","article-title":"An update of epigenetic drugs for the treatment of cancers and brain diseases: a comprehensive review","volume":"14","author":"Sahafnejad Z","year":"2023","unstructured":"Sahafnejad Z, Ramazi S, Allahverdi A. An update of epigenetic drugs for the treatment of cancers and brain diseases: a comprehensive review. Genes (Basel). 2023, 14:10.3390\/genes14040873","journal-title":"Genes (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/hir.12295","article-title":"Application of bibliometrics in medicine: a historical bibliometrics analysis","volume":"38","author":"Kokol P","year":"2021","unstructured":"Kokol P, Bla\u017eun Vo\u0161ner H, Zavr\u0161nik J. Application of bibliometrics in medicine: a historical bibliometrics analysis. Health Info Libr J. 2021, 38:125-38. 10.1111\/hir.12295","journal-title":"Health Info Libr J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00052-2","article-title":"Gastric cancer","volume":"405","author":"Sundar R","year":"2025","unstructured":"Sundar R, Nakayama I, Markar SR, et al.. Gastric cancer. Lancet. 2025, 405:2087-102. 10.1016\/S0140-6736(25)00052-2","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-024-02094-y","article-title":"Severe induction of aberrant DNA methylation by nodular gastritis in adults","volume":"59","author":"Sasaki A","year":"2024","unstructured":"Sasaki A, Takeshima H, Yamashita S, et al.. Severe induction of aberrant DNA methylation by nodular gastritis in adults. J Gastroenterol. 2024, 59:442-56. 10.1007\/s00535-024-02094-y","journal-title":"J Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-023-02055-x","article-title":"Marked intestinal trans-differentiation by autoimmune gastritis along with ectopic pancreatic and pulmonary trans-differentiation","volume":"59","author":"Takeuchi C","year":"2024","unstructured":"Takeuchi C, Sato J, Yamamichi N, et al.. Marked intestinal trans-differentiation by autoimmune gastritis along with ectopic pancreatic and pulmonary trans-differentiation. J Gastroenterol. 2024, 59:95-108. 10.1007\/s00535-023-02055-x","journal-title":"J Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2916","article-title":"Poor survival is associated with the methylated degree of zinc-finger protein 545 (ZNF545) DNA promoter in gastric cancer","volume":"6","author":"Deng J","year":"2015","unstructured":"Deng J, Liang H, Ying G, et al.. Poor survival is associated with the methylated degree of zinc-finger protein 545 (ZNF545) DNA promoter in gastric cancer. Oncotarget. 2015, 6:4482-95. 10.18632\/oncotarget.2916","journal-title":"Oncotarget"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.140067","article-title":"The survival decrease in gastric cancer is associated with the methylation of B-cell CLL\/lymphoma 6 member B promoter","volume":"4","author":"Deng J","year":"2014","unstructured":"Deng J, Liang H, Dong Q, et al.. The survival decrease in gastric cancer is associated with the methylation of B-cell CLL\/lymphoma 6 member B promoter. Open Biol. 2014, 4:10.1098\/rsob.140067","journal-title":"Open Biol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1089\/gtmb.2020.0299","article-title":"MAFK polymorphisms located in 3\u2032-UTR are associated with severity of atrophy and CDKN2A methylation status in the gastric mucosa","volume":"25","author":"Hayashi T","year":"2021","unstructured":"Hayashi T, Shibata T, Nakamura M, et al.. MAFK polymorphisms located in 3\u2032-UTR are associated with severity of atrophy and CDKN2A methylation status in the gastric mucosa. Genet Test Mol Biomarkers. 2021, 25:255-62. 10.1089\/gtmb.2020.0299","journal-title":"Genet Test Mol Biomarkers"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-13-1","article-title":"Influence of HRH2 promoter polymorphism on aberrant DNA methylation of DAPK and CDH1 in the gastric epithelium","volume":"13","author":"Nomura T","year":"2013","unstructured":"Nomura T, Tahara T, Shiroeda H, et al.. Influence of HRH2 promoter polymorphism on aberrant DNA methylation of DAPK and CDH1 in the gastric epithelium. BMC Gastroenterol. 2013, 13:1. 10.1186\/1471-230X-13-1","journal-title":"BMC Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/mc.20759","article-title":"Effect of polymorphisms of IL-1\u03b2 and TNF-\u03b1 genes on CpG island hyper methylation (CIHM) in the nonneoplastic gastric mucosa","volume":"50","author":"Tahara T","year":"2011","unstructured":"Tahara T, Shibata T, Nakamura M, et al.. Effect of polymorphisms of IL-1\u03b2 and TNF-\u03b1 genes on CpG island hyper methylation (CIHM) in the nonneoplastic gastric mucosa. Mol Carcinog. 2011, 50:835-45. 10.1002\/mc.20759","journal-title":"Mol Carcinog"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12325","article-title":"Epigenetic silencing of DACH1 induces the invasion and metastasis of gastric cancer by activating TGF-\u03b2 signalling","volume":"18","author":"Yan W","year":"2014","unstructured":"Yan W, Wu K, Herman JG, et al.. Epigenetic silencing of DACH1 induces the invasion and metastasis of gastric cancer by activating TGF-\u03b2 signalling. J Cell Mol Med. 2014, 18:2499-511. 10.1111\/jcmm.12325","journal-title":"J Cell Mol Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2217\/epi.14.92","article-title":"Epigenetic changes and functional study of HOXA11 in human gastric cancer","volume":"7","author":"Cui YY","year":"2015","unstructured":"Cui YY, Gao D, Linghu EQ, et al.. Epigenetic changes and functional study of HOXA11 in human gastric cancer. Epigenomics. 2015, 7:201-13. 10.2217\/epi.14.92","journal-title":"Epigenomics"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-328332","article-title":"Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities","volume":"72","author":"Xu C","year":"2023","unstructured":"Xu C, Huang KK, Law JH, et al.. Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities. Gut. 2023, 72:1651-63. 10.1136\/gutjnl-2022-328332","journal-title":"Gut"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00970-3","article-title":"Integrative epigenomic and high-throughput functional enhancer profiling reveals determinants of enhancer heterogeneity in gastric cancer","volume":"13","author":"Sheng T","year":"2021","unstructured":"Sheng T, Ho SW, Ooi WF, et al.. Integrative epigenomic and high-throughput functional enhancer profiling reveals determinants of enhancer heterogeneity in gastric cancer. Genome Med. 2021, 13:158. 10.1186\/s13073-021-00970-3","journal-title":"Genome Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.06.043","article-title":"ADAR-mediated RNA editing predicts progression and prognosis of gastric cancer","volume":"151","author":"Chan TH","year":"2016","unstructured":"Chan TH, Qamra A, Tan KT, et al.. ADAR-mediated RNA editing predicts progression and prognosis of gastric cancer. Gastroenterology. 2016, 151:637-50.e10. 10.1053\/j.gastro.2016.06.043","journal-title":"Gastroenterology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29627","article-title":"Current perspectives toward the identification of key players in gastric cancer microRNA dysregulation","volume":"138","author":"Ishimoto T","year":"2016","unstructured":"Ishimoto T, Baba H, Izumi D, et al.. Current perspectives toward the identification of key players in gastric cancer microRNA dysregulation. Int J Cancer. 2016, 138:1337-49. 10.1002\/ijc.29627","journal-title":"Int J Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004504","article-title":"Methylation subtypes and large-scale epigenetic alterations in gastric cancer","volume":"4","author":"Zouridis H","year":"2012","unstructured":"Zouridis H, Deng N, Ivanova T, et al.. Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci Transl Med. 2012, 4:156ra140. 10.1126\/scitranslmed.3004504","journal-title":"Sci Transl Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-017-4740-6","article-title":"Bioinformatics-based identification of methylated-differentially expressed genes and related pathways in gastric cancer","volume":"62","author":"Li H","year":"2017","unstructured":"Li H, Liu JW, Liu S, Yuan Y, Sun LP. Bioinformatics-based identification of methylated-differentially expressed genes and related pathways in gastric cancer. Dig Dis Sci. 2017, 62:3029-39. 10.1007\/s10620-017-4740-6","journal-title":"Dig Dis Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8523","article-title":"Promoter methylation of RNF180 is associated with H.pylori infection and serves as a marker for gastric cancer and atrophic gastritis","volume":"7","author":"Han F","year":"2016","unstructured":"Han F, Sun LP, Liu S, et al.. Promoter methylation of RNF180 is associated with H.pylori infection and serves as a marker for gastric cancer and atrophic gastritis. Oncotarget. 2016, 7:24800-9. 10.18632\/oncotarget.8523","journal-title":"Oncotarget"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02274-3","article-title":"Expression and prognostic potential of ribosome 18S RNA m(6)A methyltransferase METTL5 in gastric cancer","volume":"21","author":"Wang Z","year":"2021","unstructured":"Wang Z, Liu J, Yang Y, Xing C, Jing J, Yuan Y. Expression and prognostic potential of ribosome 18S RNA m(6)A methyltransferase METTL5 in gastric cancer. Cancer Cell Int. 2021, 21:569. 10.1186\/s12935-021-02274-3","journal-title":"Cancer Cell Int"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0630","article-title":"Expression profiles and prognostic roles of m6A writers, erasers and readers in gastric cancer","volume":"17","author":"Jing JJ","year":"2021","unstructured":"Jing JJ, Zhao X, Li H, Sun LP, Yuan Y. Expression profiles and prognostic roles of m6A writers, erasers and readers in gastric cancer. Future Oncol. 2021, 17:2605-20. 10.2217\/fon-2020-0630","journal-title":"Future Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.08.128","article-title":"The epigenetic silencing of LIMS2 in gastric cancer and its inhibitory effect on cell migration","volume":"349","author":"Kim SK","year":"2006","unstructured":"Kim SK, Jang HR, Kim JH, et al.. The epigenetic silencing of LIMS2 in gastric cancer and its inhibitory effect on cell migration. Biochem Biophys Res Commun. 2006, 349:1032-40. 10.1016\/j.bbrc.2006.08.128","journal-title":"Biochem Biophys Res Commun"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2217\/epi-2020-0290","article-title":"Specific epigenetic age acceleration patterns among four molecular subtypes of gastric cancer and their prognostic value","volume":"13","author":"Zhou YJ","year":"2021","unstructured":"Zhou YJ, Lu XF, Meng JL, et al.. Specific epigenetic age acceleration patterns among four molecular subtypes of gastric cancer and their prognostic value. Epigenomics. 2021, 13:767-78. 10.2217\/epi-2020-0290","journal-title":"Epigenomics"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24219","article-title":"DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: Its possible involvement in the formation of epigenetic field defect","volume":"124","author":"Ando T","year":"2009","unstructured":"Ando T, Yoshida T, Enomoto S, et al.. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: Its possible involvement in the formation of epigenetic field defect. Int J Cancer. 2009, 124:2367-74. 10.1002\/ijc.24219","journal-title":"Int J Cancer"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1159\/000486354","article-title":"Epigenetic Silencing of the MLH1 Promoter in Relation to the Development of Gastric Cancer and its use as a Biomarker for Patients with Microsatellite Instability: a Systematic Analysis","volume":"45","author":"Hu G","year":"2018","unstructured":"Hu G, Qin L, Zhang X, Ye G, Huang T. Epigenetic Silencing of the MLH1 Promoter in Relation to the Development of Gastric Cancer and its use as a Biomarker for Patients with Microsatellite Instability: a Systematic Analysis. Cell Physiol Biochem. 2018, 45:148-62. 10.1159\/000486354","journal-title":"Cell Physiol Biochem"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218338","article-title":"Methylomics analysis identifies a putative STAT3 target, SPG20, as a noninvasive epigenetic biomarker for early detection of gastric cancer","volume":"14","author":"Wei KL","year":"2019","unstructured":"Wei KL, Chou JL, Chen YC, Jin H, Chuang YM, Wu CS, Chan MW. Methylomics analysis identifies a putative STAT3 target, SPG20, as a noninvasive epigenetic biomarker for early detection of gastric cancer. PLoS One. 2019, 14:e0218338. 10.1371\/journal.pone.0218338","journal-title":"PLoS One"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.02.03","article-title":"DNA methylation drives a new path in gastric cancer early detection: current impact and prospects","volume":"11","author":"Wang X","year":"2024","unstructured":"Wang X, Dong Y, Zhang H, et al.. DNA methylation drives a new path in gastric cancer early detection: current impact and prospects. Genes Diseases. 2024, 11:847-60. 10.1016\/j.gendis.2023.02.03","journal-title":"Genes Diseases"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1511","article-title":"Novel DNA methylation markers for early detection of cardia gastric adenocarcinoma and esophageal squamous cell carcinoma","volume":"35","author":"Fan Z","year":"2024","unstructured":"Fan Z, Hao J, He F, et al.. Novel DNA methylation markers for early detection of cardia gastric adenocarcinoma and esophageal squamous cell carcinoma. Ann Oncol. 2024, 35:898-898. 10.1016\/j.annonc.2024.08.1511","journal-title":"Ann Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000278","article-title":"DNA methylation-targeted drugs","volume":"23","author":"Da Costa EM","year":"2017","unstructured":"Da Costa EM, McInnes G, Beaudry A, Raynal NJ. DNA methylation-targeted drugs. Cancer J. 2017, 23:270-6. 10.1097\/PPO.0000000000000278","journal-title":"Cancer J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.4062\/biomolther.2018.061","article-title":"Combinatorial antitumor activity of oxaliplatin with epigenetic modifying agents, 5-Aza-CDR and FK228, in human gastric cancer cells","volume":"26","author":"Park JK","year":"2018","unstructured":"Park JK, Seo JS, Lee SK, Chan KK, Kuh HJ. Combinatorial antitumor activity of oxaliplatin with epigenetic modifying agents, 5-Aza-CDR and FK228, in human gastric cancer cells. Biomol Ther (Seoul). 2018, 26:591-8. 10.4062\/biomolther.2018.061","journal-title":"Biomol Ther (Seoul)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.06.022","article-title":"Non-coding RNAs in gastric cancer","volume":"493","author":"Xie S","year":"2020","unstructured":"Xie S, Chang Y, Jin H, et al.. Non-coding RNAs in gastric cancer. Cancer Lett. 2020, 493:55-70. 10.1016\/j.canlet.2020.06.022","journal-title":"Cancer Lett"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00450-x","article-title":"The role of m6A modification in the biological functions and diseases","volume":"6","author":"Jiang X","year":"2021","unstructured":"Jiang X, Liu B, Nie Z, et al.. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021, 6:74. 10.1038\/s41392-020-00450-x","journal-title":"Signal Transduct Target Ther"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-018-0888-9","article-title":"Synergistic triad epistasis of epigenetic H3K27me modifier genes, EZH2, KDM6A, and KDM6B, in gastric cancer susceptibility","volume":"22","author":"Lee SW","year":"2019","unstructured":"Lee SW, Park DY, Kim MY, Kang C. Synergistic triad epistasis of epigenetic H3K27me modifier genes, EZH2, KDM6A, and KDM6B, in gastric cancer susceptibility. Gastric Cancer. 2019, 22:640-4. 10.1007\/s10120-018-0888-9","journal-title":"Gastric Cancer"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2024.2428280","article-title":"High neutrophil-to-lymphocyte ratio at Helicobacter pylori eradication increases the risk of eradication failure and post-eradication gastric cancer","volume":"59","author":"Yasuda T","year":"2024","unstructured":"Yasuda T, Yagi N, Omatsu T, et al.. High neutrophil-to-lymphocyte ratio at Helicobacter pylori eradication increases the risk of eradication failure and post-eradication gastric cancer. Scand J Gastroenterol. 2024, 59:1277-88. 10.1080\/00365521.2024.2428280","journal-title":"Scand J Gastroenterol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2019.03.007","article-title":"Can CpG methylation serve as surrogate markers for immune infiltration in cancer?","volume":"143","author":"Bacolod MD","year":"2019","unstructured":"Bacolod MD, Barany F, Fisher PB. Can CpG methylation serve as surrogate markers for immune infiltration in cancer?. Adv Cancer Res. 2019, 143:351-84. 10.1016\/bs.acr.2019.03.007","journal-title":"Adv Cancer Res"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1089\/gtmb.2020.0131","article-title":"Elevated SYNC expression is associated with gastric tumorigenesis and infiltration of M2-polarized macrophages in the gastric tumor immune microenvironment","volume":"25","author":"Wang D","year":"2021","unstructured":"Wang D, Deng L, Xu X, Ji Y, Jiao Z. Elevated SYNC expression is associated with gastric tumorigenesis and infiltration of M2-polarized macrophages in the gastric tumor immune microenvironment. Genet Test Mol Biomarkers. 2021, 25:236-46. 10.1089\/gtmb.2020.0131","journal-title":"Genet Test Mol Biomarkers"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2024.12543","article-title":"YTHDF1 regulates immune cell infiltration in gastric cancer via interaction with p53","volume":"27","author":"Liao Q","year":"2024","unstructured":"Liao Q, Xiong J. YTHDF1 regulates immune cell infiltration in gastric cancer via interaction with p53. Exp Ther Med. 2024, 27:255. 10.3892\/etm.2024.12543","journal-title":"Exp Ther Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-024-01805-9","article-title":"Impaired ARID1A expression attenuated the immune response in gastric cancer via histone acetylation","volume":"17","author":"Tang Y","year":"2025","unstructured":"Tang Y, Zhang R, Mao G, et al.. Impaired ARID1A expression attenuated the immune response in gastric cancer via histone acetylation. Clin Epigenetics. 2025, 17:2. 10.1186\/s13148-024-01805-9","journal-title":"Clin Epigenetics"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202204910","article-title":"m(6) a reader YTHDF1-targeting engineered small extracellular vesicles for gastric cancer therapy via epigenetic and immune regulation","volume":"35","author":"You Q","year":"2023","unstructured":"You Q, Wang F, Du R, et al.. m(6) a reader YTHDF1-targeting engineered small extracellular vesicles for gastric cancer therapy via epigenetic and immune regulation. Adv Mater. 2023, 35:e2204910. 10.1002\/adma.202204910","journal-title":"Adv Mater"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/476628-global-research-trends-in-gastric-cancer-epigenetics-from-2005-to-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:06:59Z","timestamp":1793689619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/476628-global-research-trends-in-gastric-cancer-epigenetics-from-2005-to-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":43,"URL":"https:\/\/doi.org\/10.7759\/cureus.106195","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}